Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 1009-1017, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kress, B. C.
Right arrow Articles by Santora, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kress, B. C.
Right arrow Articles by Santora, A. C., II
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1999;45:1009-1017.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Use of Bone Alkaline Phosphatase to Monitor Alendronate Therapy in Individual Postmenopausal Osteoporotic Women

Barry C. Kress1,a, Isaac A. Mizrahi1, Karen W. Armour1, Robert Marcus2, Ronald D. Emkey3 and Arthur C. Santora, II4

1 Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc., San Diego, CA 92196.

2 Aging Study Group, Veterans Administration Medical Center, and Division of Endocrinology, Gerontology, and Metabolism, Stanford University School of Medicine, Palo Alto, CA 94304.

3 Reading Hospital Medical Center, Bone Research Center, West Reading, PA 19611.

4 Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ 07065.
a Address correspondence to this author at: Hybritech Incorporated, P.O. Box 269006, San Diego, CA 92196-9006.

Background: Biochemical bone markers are sensitive to the changes in bone turnover that result from treatment of postmenopausal osteoporotic women with antiresorptive therapies. Although information is available on the use of bone markers in monitoring therapy in groups of subjects, less is known regarding how these markers perform in individual patients.

Methods: Serum bone alkaline phosphatase (bone ALP) concentrations, measured with the Tandem® Ostase® assay, were used to monitor the biochemical response of bone in postmenopausal women with osteoporosis receiving either 10 mg/day alendronate therapy (n = 74) or calcium supplementation (n = 148) for 24 months.

Results: Bone ALP decreased significantly from baseline at 3 months (P <=0.0001), reaching a nadir between 3 and 6 months of alendronate therapy. The magnitude of the bone ALP decrease in the treated osteoporotic population was consistent with normalization to premenopausal concentrations. Of the 74 alendronate-treated subjects, 63 (85.1%) demonstrated a decrease from baseline in bone ALP by 6 months that exceeded the least significant change of 25%. The bone ALP decrease from baseline exceeded 25% in 72 (97%) by the end of the study.

Conclusion: The bone ALP assay is a sensitive and reliable tool that may be used to monitor the reduction in bone turnover after alendronate therapy in individual postmenopausal osteoporotic women.© 1999 American Association for Clinical Chemistry




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Med. Genet.Home page
R Zannolli, V Micheli, M A Mazzei, P Sacco, P Piomboni, E Bruni, C Miracco, M M de Santi, P Terrosi Vagnoli, L Volterrani, et al.
Hereditary xanthinuria type II associated with mental delay, autism, cortical renal cysts, nephrocalcinosis, osteopenia, and hair and teeth defects
J. Med. Genet., November 1, 2003; 40(11): e121 - 121.
[Full Text] [PDF]

Home page
 CMAJHome page
J. P. Brown and R. G. Josse
Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada
Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. P. Brown and R. G. Josse
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada
Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. R. Dufour, J. A. Lott, F. S. Nolte, D. R. Gretch, R. S. Koff, and L. B. Seeff
Diagnosis and Monitoring of Hepatic Injury. I. Performance Characteristics of Laboratory Tests
Clin. Chem., December 1, 2000; 46(12): 2027 - 2049.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.